This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Educational Foundation Kyushu Bunka Gakuen, Kaneka Corporation, National University Corporation Kumamoto University. Active years: 2026.
Company Filing History:
1 out of 2 
1 out of 1,762 
1 out of 9 Years Active: 2026
Title: Yohei Misumi: Innovator in Transthyretin Amyloidosis Treatment
Introduction
Yohei Misumi is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of transthyretin amyloidosis. His innovative work has led to the development of a unique stabilizing agent that holds promise for patients suffering from this condition.
Latest Patents
Misumi holds a patent for a transthyretin tetramer stabilizing agent, which serves as a preventing agent or progression suppressing agent for transthyretin amyloidosis. The patent details a stabilizing agent that includes glabridin, glabrene, and glabrol. This invention aims to provide a therapeutic approach to managing transthyretin amyloidosis effectively.
Career Highlights
Throughout his career, Yohei Misumi has worked with prominent organizations, including Kaneka Corporation and the Educational Foundation Kyushu Bunka Gakuen. His experience in these institutions has contributed to his expertise and innovative capabilities in the field of medical research.
Collaborations
Misumi has collaborated with notable colleagues, including Jinko Sawashita and Yukio Ando. These partnerships have likely enhanced his research and development efforts, leading to impactful advancements in his field.
Conclusion
Yohei Misumi's contributions to the treatment of transthyretin amyloidosis through his patented inventions highlight his role as a significant innovator in medical science. His work continues to inspire advancements in therapeutic solutions for complex health issues.